Brain

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing…

9 months ago

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN…

9 months ago

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

9 months ago

Arialief: We Tested It—Here’s Our Honest Arialief Review “Shocking Conclusion”

Is Arialief the breakthrough for nerve pain, numbness, and tingling through full-spectrum metabolic support? Read our real Arialief review and…

9 months ago

Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!

Is Prime Biome’s “gut-skin synergy” the secret to beating bloating, revealing clearer skin, and maintaining steady weight management? Explore real…

9 months ago

NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for…

9 months ago

PreveCeutical Announces Update to Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"…

9 months ago

Zeto Unveils NeuroPulse, the First AI-Powered Status Epilepticus Software Using Full 10-20 EEG in Collaboration with encevis

SANTA CLARA, Calif., April 2, 2025 /PRNewswire/ -- Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its…

9 months ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader…

9 months ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation…

9 months ago